AVI BioPharma, Inc., a developer of RNA-based drugs, today announced it secured increased funding of up to approximately $4.0 million under its agreement with the US Defense Threat Reduction Agency to develop, in cooperation with the Transformational Medical Technologies Initiative of the Department of Defense, one or more of AVI's nucleotide-based drug candidates targeting the pandemic H1N1 influenza virus.
119899
AVI Biopharma secures increased funding of approximately $4.0 million
44513
Can the FDA be a catalyst for innovation?
8589
$10.4 billion increase in NIH funding could increase HIV/AIDS research
1365
New drug strategy master plan being crafted --
24400
$9.8 million awarded for stem cell research
108482
Regulatory, commercial considerations are the primary drivers for biosimilar development
144293
Genzyme moves to strengthen defenses against Icahn
66180
Researchers to begin drug development projects for rare and neglected diseases
47275
Scientists discover molecular playbook to block cardiac hypertrophy
39105
Novozymes awarded USD 12.3 million contract from the US Department of Energy
103390
SurModics signs licensing and development agreement with Roche and Genentech
92657
Roche boosts offer for Genentech
40508
The ovarian cancer drug market will more than triple over the next decade, increasing from $460 million in 2011 to $1.4 billion in 2021
79889
Merck buys drug rival Schering-Plough
69958
Alimera Sciences resubmits new drug application
70332
Merck to buy insulin developer
86813
Viralheat raises $4.25 million in series a funding